Arcturus Therapeutics
ARCT
127 hedge funds and large institutions have $783M invested in Arcturus Therapeutics in 2020 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 54 increasing their positions, 28 reducing their positions, and 20 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 28
65% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 20
64% more call options, than puts
Call options by funds: $27M | Put options by funds: $16.5M
29% more capital invested
Capital invested by funds: $606M → $783M (+$177M)
11.48% more ownership
Funds ownership: 63.2% → 74.68% (+11%)
11% more funds holding
Funds holding: 114 → 127 (+13)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$74.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$64.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$37.8M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$28.6M |
| 5 |
O
OrbiMed
New York
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$25.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$19.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$10.5M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$10.4M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$9.35M |
ARCT Hedge Fund Activity: Q3 2020 in Review
127 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q3 2020, worth a combined $783M — up 29% from $606M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ARCT positions and 20 closed out — a net gain of 13 holders — while 54 added to existing stakes and 28 trimmed.
The largest buyer was HealthCor Management, adding an estimated $74.5M. The largest seller was Deutsche Bank, cutting an estimated $25.4M.
- 127 institutional investors held Arcturus Therapeutics (ARCT) as of Q3 2020, up from 114 in Q2 2020.
- Funds reported $783M of Arcturus Therapeutics stock for Q3 2020, up 29% quarter-over-quarter.
- 33 funds opened new Arcturus Therapeutics positions in Q3 2020 and 20 closed out, a net change of +13 holders.
- The largest Arcturus Therapeutics buyer in Q3 2020 was HealthCor Management, an estimated $74.5M added.
- The largest Arcturus Therapeutics seller in Q3 2020 was Deutsche Bank, an estimated $25.4M sold.
Based on aggregated 13F filings for Q3 2020.